Portal de investigación
“International multicentric phase II trial to evaluate the efficacy and safety of pirtobrutinib in combination with rituximab in patients with indolent clinical forms of mantle cell lymphoma”.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
GELTAMO (GRUPO ESPAÑOL DE LINFOMA Y TRASPLANTE AUTÓLOGO DE MÉDULA ÓSEA)
Cita
“International multicentric phase II trial to evaluate the efficacy and safety of pirtobrutinib in combination with rituximab in patients with indolent clinical forms of mantle cell lymphoma”. (IMCL-2023). GELTAMO (GRUPO ESPAÑOL DE LINFOMA Y TRASPLANTE AUTÓLOGO DE MÉDULA ÓSEA). 2025IP:RAFAEL ANDREU LAPIEDRA.